[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuropathology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuropathology":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,80,104,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100544190","cognitive-functioning-in-adults-with-somatic-diseases-and-general-population-from-a-biopsychosocial-perspective-100544190",false,"NCT06365658","Cognitive Functioning in Adults With Somatic Diseases and General Population From a Biopsychosocial Perspective","Cognitive Functioning Profiles in Adults With Neurologically Recognized Aphasic Syndromes and General Population From a Biopsychosocial Perspective","Inclusion criteria for general population\u002Fcontrol group:\n\n* age from 18 to 60 y.o.\n\nInclusion criteria for neurologically recognized aphasic syndromes\n\n* age above 18 y.o.\n* neurologically recognized aphasic syndromes\n\nInclusion criteria for seniors:\n\n* age above 60 y.o.\n\nExclusion criteria for general population\u002Fcontrol group:\n\n* age less then 18 y.o.\n* neurologically recognized aphasic syndromes\n\nExclusion criteria for neurologically recognized aphasic syndromes\n\n* age less then 18 y.o.\n* no neurologically recognized aphasic syndromes\n\nExclusion criteria for seniors\n\n* age less then 60 y.o.\n* diseases of the nervous system, such as: stroke, craniocerebral trauma, neuroinfections, neurodegenerative diseases\n* mental disorders such as depression, psychotic disorders, anxiety disorders, addictions",true,"ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to investigate cognitive functioning profiles in adults with neurologically recognized aphasic syndromes and general population.\n\nThe study group consist of minimal 600 adults (over 18 y.o.) who will be examined by qualified diagnosticians. Participants will be evaluated with tasks related to the studied variables: memory, learning and language. Furthermore informations regarding past and present health condition will be collected from participants.\n\nThe main questions it aims to answer are:\n\n1. What is the profile of memory and learning among polish adults?\n2. Do gender and age moderates patterns of memory and learning functioning among polish adults?\n3. What is a specific pattern of language functioning in adults with neurologically recognized aphasic syndromes?\n4. Do gender moderates specific patterns of language functioning in adults with neurologically recognized aphasic syndromes?\n\nResearchers will compare the following groups of adults:\n\n1. general population\u002Fcontrol group\n2. with neurologically recognized aphasic syndromes\n3. seniors (over 60 y.o.)",[25,26,27],"Aphasia","Development, Human","Neuropathology",[29,30,31,32,33,34],"aphasia","memory","learning","language","adults","seniors","RECRUITING","2026-01-22",{"date":38,"type":39},"2026-01-26","ACTUAL",{"date":41,"type":39},"2023-07-03",{"date":43,"type":21},"2026-12",{"name":45,"class":46},"Bartosz M. Radtke","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100487652","biomarkers-of-sleep-wake-cycle-in-prodromal-alzheimers-disease-role-in-cognitive-decline-100487652","NCT05629871","Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?","ALZ-OREX","Inclusion Criteria:\n\n* Diagnosis of mild Alzheimer's disease with a Mini Mental State (MMS) between 21-30\n* The presence of a family carer to complete neuropsychological scales, questionnaires and sleep diaries\n* Having a neurological assessment and\u002For follow-up requiring blood and cerebrospinal fluid (CSF) sampling with biomarkers for diagnostic purposes\n* Patient who had a lumbar puncture less than one year ago or patient with a scheduled lumbar puncture as part of care\n* Signed informed consent\n* Able to carry out all visits and follow study procedures\n* Affiliation to the French social security system\n\nExclusion Criteria:\n\n* Genetic form of alzheimer's disease\n* Insufficient clinical and paraclinical information for the diagnosis of AD\n* Anticholinesterase and\u002For memantine treatment or on stable doses for at least 3 months\n* Use of antidepressants, anxiolytics, hypnotics, neuroleptics, 15 days before inclusion\n* Patient living in a nursing home\n* Illiteracy or inability to perform psycho-behavioural tests\n* Major physical or neurosensory problems that may interfere with the tests\n* Initial contraindication to diagnostic lumbar puncture (LP) (spinal surgery, skin infection, haemostasis abnormality, intracranial hypertension, severe coagulation disorders, curative anticoagulant therapy, severe liver failure)\n* Refusal to perform a diagnostic lumbar puncture\n* Contraindication to the use of E-Celsius: people weighing less than 40 kg, with intestinal disorders, with known swallowing disorders\n* Patient deprived of liberty, by judicial or administrative decision;\n* Major protected by law;\n* Patient in a period of relative exclusion from another protocol or for whom the maximum annual compensation of €4500 has been reached;\n* Refusal to participate in the protocol.","50 Years","85 Years",{"count":58,"type":21},132,"INTERVENTIONAL",[61],"NA","Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain. There is a link between the accumulation of Aβ peptides and the deterioration of sleep, but current knowledge does not confirmed this link. The objective of this study is to define whether there is a link between cognitive decline and sleep disorders. If a correlation is found, this could allow earlier treatment of sleep disorders in the longer term in order to slow the development of AD.",[27],[65,66,67,68],"cognitive composite score","sleep","biomarkers","cognitive decline","2025-10-02",{"date":71,"type":39},"2025-10-07",{"date":73,"type":39},"2023-04-17",{"date":75,"type":21},"2027-07-01",{"name":77,"class":78},"University Hospital, Montpellier","OTHER",3,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":88,"targetDuration":4,"studyType":59,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":47},"100489161","sleep-impairment-in-subjects-at-risk-of-developing-alzheimers-disease-100489161","NCT05649514","Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease","Objective Sleep Impairment in APOEε4\u002Fε4 Subjects at Risk of Developing Alzheimer's Disease: Risk Factor for Cognitive Decline?","WAVE-APOE4","Inclusion Criteria:\n\n* Diagnosis of mild Alzheimer's disease with a MMS between 21-30\n* Without anticholinesterase and\u002For memantine treatment or on stable doses for at least 3 months\n* No antidepressant or anxiolytic treatment or stopped for at least 15 days\n* The presence of a family carer to complete neuropsychological scales, questionnaires and sleep diaries\n* Signed informed consent\n* Able to carry out all visits and follow study procedures\n* Affiliation to the French social security system\n\nExclusion Criteria:\n\n* Genetic form of alzheimer's disease\n* Insufficient clinical and paraclinical information for the diagnosis of AD\n* Patient living in a nursing home\n* Illiteracy or inability to perform psycho-behavioural tests\n* Major physical or neurosensory problems that may interfere with the tests\n* Patient deprived of liberty, by judicial or administrative decision;\n* Major depression according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5)\n* Major protected by law;\n* Short-term life-threatening conditions",{"count":89,"type":21},50,[61],"Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain. There is a link between the accumulation of Aβ peptides and the deterioration of sleep, but current knowledge does not confirmed this link. The objective of this study is to define whether there is a link between cognitive decline and sleep disorders. If a correlation is found, this could allow earlier treatment of sleep disorders in the longer term in order to slow the development of AD.\n\nTreatment protocols in the field of Alzheimer's disease (AD) are directed towards participants at risk of developing the disease, such as those who carry at least one ε4 allele on apolipoprotein E (APOE ε4). An individual with 2 ε4 copies has a 30-55% risk of developing AD with an age of onset around 68 years and a dose effect of the allele on risk and age of onset of symptoms.",[27,93,94],"Cognitive Decline","Sleep Disorder",[65,66,67,68],"2025-06-23",{"date":98,"type":39},"2025-06-27",{"date":100,"type":39},"2025-02-05",{"date":102,"type":21},"2027-12-01",{"name":77,"class":78},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":47},"100440546","neuropathological-changes-of-the-intestinal-wall-in-patients-with-bowel-evacuation-disorders-100440546","NCT05016700","Neuropathological Changes of the Intestinal Wall in Patients With Bowel Evacuation Disorders","Correlation of Clinical Symptoms With Neuromorphological Changes of the Colorectal Wall in Patients With a Bowel Evacuation Disorder","Constipation","Inclusion Criteria:\n\n* obstructive defecation disorder scheduled for surgery\n* must be able to undergo surgery\n* \\> 18 years of age\n* informed consent\n\nExclusion Criteria:\n\n* no defecation disorder\n* no surgery needed\n* unable to undergo surgery\n* ≤ 18 years\n* no consent",{"count":113,"type":21},500,"Constipation and defecation disorders affect about 15% of the European population and of those up to 30% of the patients over 65 years of age. For those affected, this is associated with major restrictions in quality of life and high health care costs .\n\nThe underlying causes of constipation and defecation are complex and only partially understood.\n\nIntestinal (full wall) resections taken in clinical practice from these patients when conservative therapy has been exhausted show rarefaction of ganglion cell nests in the myenteric plexus and submucosal plexus as well as changes in cholinergic innervation.\n\nInitial histopathological investigations suggest an inflammatory genesis of this rarefaction of ganglion cell nests, which will be further characterised\u002Finvestigated in the context of this study on the basis of further histopathological and serological investigations. This may lead to novel therapeutic approaches that can causally treat the symptoms of those affected.",[116,27,117],"Defecation Disorder","Autoimmune Diseases",[27,119,120,121,122,123,124],"Defecation disorder","Autoimmune disease","Hypoganglionosis","Autoimmune ganglionitis","Neurological bowel disorder","Colon surgery","2025-03-07",{"date":127,"type":39},"2025-03-10",{"date":129,"type":39},"2019-03-20",{"date":131,"type":21},"2033-12-31",{"name":133,"class":78},"Evangelisches Klinikum Köln Weyertal gGmbH",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":47},"100576190","idiopathic-generalized-epilepsy-cognitive-and-emotional-profile-100576190","NCT06782074","Idiopathic Generalized Epilepsy Cognitive and Emotional Profile","Idiopathic Generalized Epilepsy: Cognitive, Emotional, Behavioral Functioning, and Quality of Life","Inclusion criteria:\n\nAge between 11 and 18 years Diagnosis of idiopathic generalized epilepsy\n\nExclusion criteria:\n\nAge under 11 years or over 18 years Structural or cryptogenic epilepsy Intellectual disability or borderline cognitive level Refusal to participate in the study Failure to obtain informed consent","11 Years","17 Years",{"count":144,"type":21},96,"The primary goal of the study is to explore the neurocognitive, emotional-behavioral functioning, and quality of life of adolescents with IGE, identifying key factors that affect their overall well-being.\n\nThe study involves participants and their caregivers completing standardized questionnaires. Additionally, clinical and anamnesic information will be collected to investigate the role of these variables on the emotional and executive functioning of the enrolled subjects",[147,148,27,149,150],"Epilepsy","Quality of Life","Emotional Problem","Executive Dysfunction","2025-01-13",{"date":153,"type":39},"2025-01-17",{"date":155,"type":39},"2023-06-01",{"date":157,"type":21},"2025-06-30",{"name":159,"class":78},"IRCCS National Neurological Institute \"C. Mondino\" Foundation"]